1,391 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AMGN Amgen Inc. $193.15 $127.81B Uptrend
Article Searches
Mcrae Capital Management Inc Buys Wyndham Hotels & Resorts Inc, Procter & Gamble Co, ... http://www.gurufocus.com/news/708361/mcrae-capital-management-inc-buys-wyndham-hotels--resorts-inc-procter--gamble-co-wyndham-destinations-inc-sells-barings-global-short-duration-high-yield-fund-bristolmyers-squibb-company-jm-smucker-co Jul 16, 2018 - Mcrae Capital Management Inc Buys Wyndham Hotels & Resorts Inc, Procter & Gamble Co, Wyndham Destinations Inc, Sells Barings Global Short Duration High Yield Fund, Bristol-Myers Squibb Company, JM Smucker Co, Stocks: PG,PFE,TPR,T,AMGN,HD,WH,WYND,FDX,NVT,ICE,TXN,BMY,W, release date:Jul 16, 2018
The Jim Carrey Parable http://www.gurufocus.com/news/708295/the-jim-carrey-parable Jul 16, 2018 - The Jim Carrey Parable, Stocks: AMZN,FB,GOOGL,TGT,KR,WBA,AMGN,MRK,PFE,JNJ,DISCA, Howard Marks, release date:Jul 16, 2018
Pacira Focused on Exparel Development Amid Competition http://www.zacks.com/stock/news/311702/pacira-focused-on-exparel-development-amid-competition?cid=CS-ZC-FT-311702 Jul 16, 2018 - Pacira (PCRX) focuses on the label expansion of its flagship product, Exparel.
Health Is Expensive – These Stocks Are Primed for Growth http://www.gurufocus.com/news/707902/health-is-expensive--these-stocks-are-primed-for-growth Jul 16, 2018 - Health Is Expensive – These Stocks Are Primed for Growth, release date:Jul 15, 2018
Allergan: Crucial Period Ahead For Company As Activist Pressure Mounts https://seekingalpha.com/article/4187408-allergan-crucial-period-ahead-company-activist-pressure-mounts?source=feed_sector_healthcare Jul 16, 2018 - Allergan is under pressure from activist shareholders and other investors to formulate a clear strategic plan and make more drastic changes to the company.Botox Aesthetics, Botox Migraine, and Restasi
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population http://www.zacks.com/stock/news/311579/pfizers-xtandi-gets-fda-nod-for-expanded-patient-population?cid=CS-ZC-FT-311579 Jul 16, 2018 - FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Your Daily Pharma Scoop: Advaxis Trial Cleared, Atossa Trial Proceeds, Amgen Resubmits NDA https://seekingalpha.com/article/4187399-daily-pharma-scoop-advaxis-trial-cleared-atossa-trial-proceeds-amgen-resubmits-nda?source=feed_sector_healthcare Jul 16, 2018 - FDA lifts hold on Advaxis trial.Atossa commences Phase 2 trial.Amgen files a fresh NDA.
Biotech Analysis Central Pharma News: Celgene's Protocol Change, Roche's BLA For Herceptin, Amgen's Resubmission For Osteoporosis https://seekingalpha.com/article/4187398-biotech-analysis-central-pharma-news-celgenes-protocol-change-roches-bla-herceptin-amgens?source=feed_sector_healthcare Jul 16, 2018 - Celgene amends protocol for phase 2 multiple myeloma study.FDA accepts BLA from Roche for subcutaneous version of Herceptin.Amgen and UCB resubmit BLA application for osteoporosis drug.
Is a Surprise in the Cards for Novartis in Q2 Earnings? http://www.zacks.com/stock/news/311607/is-a-surprise-in-the-cards-for-novartis-in-q2-earnings?cid=CS-ZC-FT-311607 Jul 16, 2018 - Swiss-giant Novartis (NVS) is all set to report second-quarter 2018 earnings on Jul 18. While the pharma business should maintain growth, the generic division is expected to be laggard.
Better Buy: Biogen Inc. vs. Amgen https://www.fool.com/investing/2018/07/15/better-buy-biogen-inc-vs-amgen.aspx?source=iedfolrf0000001 Jul 15, 2018 - Biogen and Amgen have been two of the best performing biotechs for a decade. But one stock clearly has an easier path toward value creation.

Pages: 123456...140

Page 1>

Related Companies

Name Exchange Price Mkt Cap
GILD Gilead Sciences, Inc. NASDAQ $76.02 $98.85B
BIIB Biogen Inc. NASDAQ $344.1 $72.61B
SGEN Seattle Genetics, Inc. NASDAQ $69.44 $10.99B
NBIX Neurocrine Biosciences, Inc. NASDAQ $101.4 $9.12B
BLUE bluebird bio, Inc. NASDAQ $178.35 $8.94B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Amgen
AMGN - Google Finance https://www.google.com/finance?q=AMGN Industry related info and international coverage Summary News
AMGN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=AMGN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options